Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.
Calcipotriol/betamethasone dipropionate foam (Enstilar®) is a once-daily synthetic vitamin D3analogue and synthetic corticosteroid fixed-dose combination foam formulation that is indicated for the topical treatment of plaque psoriasis in adults. In randomized, multicentre trials, treatment with calcipotriol/betamethasone dipropionate foam for 4 weeks resulted in greater proportions of patients achieving treatment success [of the body (i.e. trunk and/or limbs), as assessed by a physician] compared with 4 weeks' treatment with the foam vehicle, individual components as foam, or calcipotriol/betamethasone dipropionate fixed-dose combination as an ointment, or 8 weeks' treatment with the fixed-dose combination as a topical suspension. Treatment with calcipotriol/betamethasone dipropionate foam resulted in significantly lower modified psoriasis area and severity index scores and, where assessed, greater improvements from baseline to week 4 in itch-related sleep loss and health-related quality of life than its comparators; results were mixed for patient-assessed improvements in itch. Overall, adverse events were mostly mild or moderate in severity, and the most commonly reported treatment-related adverse events were application-site events. Notably, there were no reports of clinically relevant effects on calcium homeostasis or the hypothalamic-pituitary-adrenal axis. Calcipotriol/betamethasone dipropionate foam is a useful new option for patients with plaque psoriasis.
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
Esther S
ES
Kim
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
James E
JE
Frampton
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol
Clin Drug Investig. 2015 Apr;35(4):239-45
25708531
J Clin Aesthet Dermatol. 2016 Feb;9(2):34-41
27313822
J Dermatol Sci. 2016 Mar;81(3):153-64
26794805
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):119-126
27531752
J Drugs Dermatol. 2016 Aug 1;15(8):951-7
27537995
J Dermatolog Treat. 2016;27(2):120-7
26444907
Dermatol Ther (Heidelb). 2016 Sep;6(3):413-25
27358072
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028
23543539
J Eur Acad Dermatol Venereol. 2014 May;28 Suppl 2:4-9
24684738
J Am Acad Dermatol. 2011 Jul;65(1):137-74
21306785
Drugs. 2011 Apr 16;71(6):709-30
21504248
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1951-1956
27306589
J Cutan Med Surg. 2016 Jan;20(1):44-51
26224733
Lancet. 2015 Sep 5;386(9997):983-94
26025581
J Am Board Fam Med. 2013 Nov-Dec;26(6):787-801
24204077
J Am Acad Dermatol. 2008 May;58(5):826-50
18423260
J Drugs Dermatol. 2015 Dec;14(12):1468-77
26659941